Recent Updates
Recently added Catalysts

CHI-554

Phase 2

Anxiety | Small molecule | Psychiatry |Canopy Growth Corporation Common Shares|Last Updated: Jun 2, 2021

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment84
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT04577612A Randomized Controlled Test of the Effects of CHI-554 on Fear.PHASE2 COMPLETED 84 — — Aug 1, 2020May 1, 2021Jun 2, 2021 - —
Unlock Drug Trial Details
Study Design & Arms
Interventions
NameTypeDescription
CHI-554DRUGhemp-derived CBD in MCT oil
Unlock Study Design Details
Competitive Landscape -Anxiety Disorders 31 trials
CompanyTickerTrialsLead PhaseDrugs
Definium Therapeutics, Inc.DFTX2PHASE3MM120
Vistagen Therapeutics, Inc.VTGN3PHASE3Fasedienol, Fasedienol - Fasedienol
Vanda Pharmaceuticals Inc.VNDA1PHASE3VQW-765
AbbVie, Inc.ABBV1PHASE2ABBV-932, Antidepressant Therapy
Cybin, Inc.HELP1PHASE2CYB004
Masimo CorporationMASI1PHASE1Diprivan , Astra-Zeneca
Psyence Biomedical Ltd.PBM1PHASE2Psilocybin therapy
Neuronetics, Inc.STIM2 — Patients treated with Esketamine
Aura Biosciences IncAURA1 — Undisclosed
Cooper Companies, Inc.COO1NAUndisclosed
Vera Therapeutics, Inc. Class AVERA1NAUndisclosed
Design Therapeutics, Inc.DSGN1NAUndisclosed
Unlock Competitive Intelligence